Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2021;71(3):209–49.
Sugarman ET, Zhang G, Shay JW. In perspective: an replace on telomere focusing on in most cancers. Mol Carcinog. 2019;58(9):1581–8.
Mizukoshi E, Kaneko S. Telomerase-targeted most cancers immunotherapy. Int J Mol Sci. 2019;20(8):1823.
Man RJ, Chen LW, Zhu HL. Telomerase inhibitors: a patent overview (2010–2015). Knowledgeable Opin Ther Pat. 2016;26(6):679–88.
Mender I, LaRanger R, Luitel Ok, Peyton M, Girard L, Lai TP, Batten Ok, Cornelius C, Dalvi MP, Ramirez M, Du W, Wu LF, Altschuler SJ, Brekken R, Martinez ED, Minna JD, Wright WE, Shay JW. Telomerase-mediated technique for overcoming non-small cell lung most cancers focused remedy and chemotherapy resistance. Neoplasia. 2018;20(8):826–37.
Sengupta S, Sobo M, Lee Ok, Senthil Kumar S, White AR, Mender I, Fuller C, Chow LML, Fouladi M, Shay JW, Drissi R. Induced telomere harm to deal with telomerase expressing therapy-resistant pediatric mind tumors. Mol Most cancers Ther. 2018;17(7):1504–14.
Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser Ok, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson Ok, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. Induction of telomere dysfunction prolongs illness management of therapy-resistant melanoma. Scientific Most cancers Res Off J Am Assoc Most cancers Res. 2018;24(19):4771–84.
Yu S, Wei S, Savani M, Lin X, Du Ok, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, Charbonneau CM, Sugarman E, Bowie M, Hariharan S, Waitkus M, Jiang W, McLendon RE, Pan E, Khasraw M, Walsh KM, Lu Y, Herlyn M, Mills G, Herbig U, Wei Z, Keir ST, Flaherty Ok, Liu L, Wu Ok, Shay JW, Abdullah Ok, Zhang G, Ashley DM. A modified nucleoside 6-Thio-2’-deoxyguanosine displays antitumor exercise in gliomas. Clin Most cancers Res Off J Am Assoc Most cancers Res. 2021;27(24):6800–14.
Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2’-deoxyguanosine. Most cancers Discov. 2015;5(1):82–95.
Mender I, Gryaznov S, Shay JW. A novel telomerase substrate precursor quickly induces telomere dysfunction in telomerase optimistic most cancers cells however not telomerase silent regular cells. Oncoscience. 2015;2(8):693–5.
Mender I, Zhang A, Ren Z, Han C, Deng Y, Siteni S, Li H, Zhu J, Vemula A, Shay JW, Fu YX. Telomere stress potentiates STING-dependent anti-tumor immunity. Most cancers Cell. 2020;38(3):400-411.e6.
Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and demise. Nat Immunol. 2022;23(4):487–500.
Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell demise and DAMPs in most cancers remedy. Nat Rev Most cancers. 2012;12(12):860–75.
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo Ok. Immunogenic cell demise prompts the tumor immune microenvironment to spice up the immunotherapy effectivity. Adv Sci. 2022;9(22):e2201734.
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, Zhao L, Spisek R, Kroemer G, Galluzzi L. Detection of immunogenic cell demise and its relevance for most cancers remedy. Cell Demise Dis. 2020;11(11):1013.
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, Kostopoulos IV, Antimissari E, Terzoudi G, Georgakilas AG, Armpilia C, Papageorgis P, Kastritis E, Terpos E, Dimopoulos MA, Kalbacher H, Livaniou E, Christodoulou MI, Tsitsilonis OE. Immunogenic cell demise, DAMPs and Prothymosin α as a putative anticancer immune response biomarker. Cells. 2022;11(9):1415.
Tatsuno Ok, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL, Galluzzi L. Extracorporeal photochemotherapy induces bona fide immunogenic cell demise. Cell Demise Dis. 2019;10(8):578.
Ahmed A, Tait SWG. Concentrating on immunogenic cell demise in most cancers. Mol Oncol. 2020;14(12):2994–3006.
Vaes RDW, Hendriks LEL, Vooijs M, De Ruysscher D. Biomarkers of radiotherapy-induced immunogenic cell demise. Cells. 2021;10(4):930.
Nuccitelli R, McDaniel A, Anand S, Cha J, Mallon Z, Berridge JC, Uecker D. Nano-pulse stimulation is a bodily modality that may set off immunogenic tumor cell demise. J Immunother Most cancers. 2017;5:32.
Jiang M, Zeng J, Zhao L, Zhang M, Ma J, Guan X, Zhang W. Chemotherapeutic drug-induced immunogenic cell demise for nanomedicine-based most cancers chemo-immunotherapy. Nanoscale. 2021;13(41):17218–35.
Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, Cancelliere C, Di Fiore PP, Bardelli A, Penna G, Rescigno M. The EGFR-specific antibody cetuximab mixed with chemotherapy triggers immunogenic cell demise. Nat Med. 2016;22(6):624–31.
Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, Coutant F, Métivier D, Pichard E, Aucouturier P, Pierron G, Garrido C, Zitvogel L, Kroemer G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell demise. J Exp Med. 2005;202(12):1691–701.
Wang M, Duan B, Bai J, Luo Y, Ma Y. Telomerase inhibitor 6-Thio-2’-deoxyguanosine induces immunogenic cell demise in tumour cells. Chin J Cell Biol. 2024;46(2):214–25.
Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, McCarter MD. Immunosuppressive myeloid-derived suppressor cells are elevated in splenocytes from most cancers sufferers. Most cancers Immunol Immunother CII. 2017;66(4):503–13.
Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune exercise. Clin Most cancers Res Off J Am Assoc Most cancers Res. 2005;11(18):6713–21.
Qing S, Lyu C, Zhu L, Pan C, Wang S, Li F, Wang J, Yue H, Gao X, Jia R, Wei W, Ma G. Biomineralized bacterial outer membrane vesicles potentiate protected and environment friendly tumor microenvironment reprogramming for anticancer remedy. Adv Mater. 2020;32(47):2002085.
Hua L, Yang Z, Li W, Zhang Q, Ren Z, Ye C, Zheng X, Li D, Lengthy Q, Bai H, Solar W, Yang X, Zheng P, He J, Chen Y, Huang W, Ma Y. A Novel Immunomodulator supply platform based mostly on bacterial biomimetic vesicles for enhanced antitumor immunity. Superior Mater. 2021;33(43):2103923.
Li S, Zhang Q, Bai H, Huang W, Shu C, Ye C, Solar W, Ma Y. Self-assembled nanofibers elicit potent HPV16 E7-specific mobile immunity and abolish established TC-1 graft tumor. Int J Nanomed. 2019;14:8209–19.
Li S, Zhu W, Ye C, Solar W, Xie H, Yang X, Zhang Q, Ma Y. Native mucosal immunization of self-assembled nanofibers elicits sturdy antitumor results in an orthotopic mannequin of mouse genital tumors. Nanoscale. 2020;12(5):3076–89.
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Main, adaptive, and purchased resistance to most cancers immunotherapy. Cell. 2017;168(4):707–23.
Binnewies M, Roberts EW, Kersten Ok, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF. Understanding the tumor immune microenvironment (TIME) for efficient remedy. Nat Med. 2018;24(5):541–50.
Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231–5.
Huang Y, Shi Y, Wang Q, Qi T, Fu X, Gu Z, Zhang Y, Zhai G, Zhao X, Solar Q, Lin G. Enzyme responsiveness enhances the specificity and effectiveness of nanoparticles for the therapy of B16F10 melanoma. J Controll Launch Off J Managed Launch Soc. 2019;316:208–22.
Shay JW, Wright WE. Telomerase therapeutics for most cancers: challenges and new instructions. Nat Rev Drug Discovery. 2006;5(7):577–84.
Harley CB. Telomerase and most cancers therapeutics. Nat Rev Most cancers. 2008;8(3):167–79.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological results of standard chemotherapy and focused anticancer brokers. Most cancers Cell. 2015;28(6):690–714.
Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151–60.
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological elements of most cancers chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, André F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.
Gianni T, Leoni V, Sanapo M, Parenti F, Bressanin D, Barboni C, Zaghini A, Campadelli-Fiume G, Vannini A. Genotype of immunologically scorching or chilly tumors determines the antitumor immune response and efficacy by absolutely virulent retargeted oHSV. Viruses. 2021;13(9):1747.
Ni G, Yang X, Li J, Wu X, Liu Y, Li H, Chen S, Fogarty CE, Frazer IH, Chen G, Liu X, Wang T. Intratumoral injection of caerin 1.1 and 1.9 peptides will increase the efficacy of vaccinated TC-1 tumor-bearing mice with PD-1 blockade by modulating macrophage heterogeneity and the activation of CD8(+) T cells within the tumor microenvironment. Clin Trans Immunol. 2021;10(8):1335.
Noman MZ, Parpal S, Van Moer Ok, Xiao M, Yu Y, Viklund J, De Milito A, Hasmim M, Andersson M, Amaravadi RK, Martinsson J, Berchem G, Janji B. Inhibition of Vps34 reprograms chilly into scorching infected tumors and improves anti-PD-1/PD-L1 immunotherapy. Sci Adv. 2020;6(18):eaax7881.
Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a marker of T cell activation and proliferation. PLoS ONE. 2011;6(8): e24226.
Ruffell B, Coussens LM. Macrophages and therapeutic resistance in most cancers. Most cancers Cell. 2015;27(4):462–72.
Kim OY, Park HT, Dinh NTH, Choi SJ, Lee J, Kim JH, Lee SW, Gho YS. Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun. 2017;8(1):626.
Xing R, Liu G, Zhu J, Hou Y, Chen X. Useful magnetic nanoparticles for non-viral gene supply and MR imaging. Pharm Res. 2014;31(6):1377–89.
Chen H, Yan S, Zhang L, Zhao B, Zhu C, Deng G, Liu J. A self-degrading and NIR-II emissive sort I/II photosensitizer with synergistic photodynamic and photothermal properties for antibacterial and anticancer. Sens Actuators B Chem. 2024;405: 135346.
Zheng P, He J, Fu Y, Yang Y, Li S, Duan B, Yang Y, Hu Y, Yang Z, Wang M, Liu Q, Zheng X, Hua L, Li W, Li D, Ding Y, Yang X, Bai H, Lengthy Q, Huang W, Ma Y. Engineered bacterial biomimetic vesicles reprogram tumor-associated macrophages and transform tumor microenvironment to advertise innate and adaptive antitumor immune responses. ACS Nano. 2024;18(9):6863–86.
Huang Y, Gu Z, Fan Y, Zhai G, Zhao X, Solar Q, Shi Y, Lin G. Inhibition of the adenosinergic pathway: the indispensable a part of oncological remedy sooner or later. Purinergic Sign. 2019;15(1):53–67.
THIO sequenced with cemiplimab in superior NSCLC. https://tinyurl.com/mr3rjuw3 (Accessed 5 Feb, 2025).
MAIA Biotechnology declares optimistic efficacy updates for section 2 THIO-101 trial in superior non-small cell lung most cancers. https://tinyurl.com/ypuvs8e2 (Accessed 5 Feb, 2025).
Zhang Q, Huang W, Yuan M, Li W, Hua L, Yang Z, Gao F, Li S, Ye C, Chen Y, He J, Solar W, Yang X, Bai H, Ma Y. Using ATP as a brand new adjuvant promotes the induction of sturdy antitumor mobile immunity by a PLGA nanoparticle vaccine. ACS Appl Mater Interf. 2020;12(49):54399–414.
Weber R, Riester Z, Hüser L, Sticht C, Siebenmorgen A, Groth C, Hu X, Altevogt P, Utikal JS, Umansky V. IL-6 regulates CCR5 expression and immunosuppressive capability of MDSC in murine melanoma. J Immunother Most cancers. 2020;8(2):000949.
Li T, Li X, Zamani A, Wang W, Lee CN, Li M, Luo G, Eiler E, Solar H, Ghosh S, Jin J, Murali R, Ruan Q, Shi W, Chen YH. c-Rel Is a myeloid checkpoint for most cancers immunotherapy. Nature most cancers. 2020;1(5):507–17.
Li W, Hu Y, Zhang Q, Hua L, Yang Z, Ren Z, Zheng X, Huang W, Ma Y. Growth of drug-resistant Klebsiella pneumoniae vaccine through novel vesicle manufacturing expertise. ACS Appl Mater Interf. 2021;13(28):32703–15.
Zheng P, He J, Yang Z, Fu Y, Yang Y, Li W, Ding Y, Yang X, Ma Y. Neoantigen-based nanovaccine together with immune checkpoint inhibitors abolish postsurgical tumor recurrence and metastasis. Small. 2023;19(50): e2302922.
